Novartis (NYSE: NVS) reported Q2 EPS of $2.42, $0.07 better than the analyst estimate of $2.35. Revenue for the quarter came in at $14.05 billion versus the consensus estimate of $14.02 billion.

GUIDANCE

Full-year 2025 guidance 2 raised for core operating income
o Sales expected to grow high single digit (unchanged)
o Core operating income expected to grow low teens (from low double-digit)

For earnings history and earnings-related data on Novartis (NVS) click here.